Phaseline

Companies › Immunic

Immunic: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vidofludimus (IMU-838)
Dihydroorotate dehydrogenase inhibitor
DHODHPhase 3Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Relapsing-Remitting Multiple Sclerosis (RRMS)Nov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05201638Vidofludimus (IMU-838)Phase 3Multiple Sclerosis, Relapsing-RemittingNeurologyNov 2026
NCT05134441Vidofludimus (IMU-838)Phase 3Multiple SclerosisNeurologyNov 2026
NCT03846219Vidofludimus (IMU-838)Phase 2Relapsing-Remitting Multiple Sclerosis (RRMS)NeurologyDec 2029

From the company's SEC filings

Cash of $155m on 2026-06-30; operating cash outflow about $98m a year; runway about 19 months at that burn, to Jan 2028; 2 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

DHODH (1)

Companies with the same targets

Jabez Bioscience Kiora Pharmaceuticals

Companies built like this

Alpha Cognition NervGen Pharma Satellos Bioscience Coya Therapeutics PepGen

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.